|
|
FDA Grants Epeius Biotechnologies' Rexin-G A Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
Tue, 08 Jul 2008, 18:01:25 EDT
Edited by Debra Tone
SAN MARINO, Calif., July 8 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of all soft tissue sarcomas. This latest approval is the third clinical indication for which Rexin-G has been formally recognized by the FDA in the United States. This latest approval for Rexin-G validates the company's remarkable strategy of addressing a global unmet medical need by caring for one individual patient, one particular type of tumor, one otherwise intractable cancer at a time.
 The clinical development of Rexin-G worldwide has been equally remarkable. Beginning with the most serious and life-threatening forms of pancreatic cancer, Rexin-G has demonstrated unprecedented single-agent efficacy in metastatic cancers of the colon, breast, skin, lung, and bone in a progressive program of expanded access that continues to achieve historic milestones. Eschewing any trappings of personal accomplishment, Epeius gives credit to the dedication and efforts of the many pioneering oncologists, the progressive medical institutions, and the conscientious regulatory agencies who have all served to guide Rexin-G, with its elegant tumor-targeting nanotechnologies, to the bedside. Most recently, Rexin-G has been approved in the Philippines for the treatment of all solid tumors that are refractory to standard chemotherapies.
In addition to developing the first and so far only tumor-targeted genetic medicine that has been validated in the clinic, Epeius Biotechnologies has assumed the daunting responsibilities of advancing these enabling platform technologies safely and effectively through an arduous array of regulatory hurdles and medical proofs-of-principle that are required for a radically new medicine. Initial Phase I safety studies established the general safety of Rexin-G, followed by Phase I/II efficacy studies where optimal clinical protocols were established for each particular type of tumor.
The importance of these progressive dose-escalation studies-which clearly establish safety before escalating to more potent tumoricidal dose levels-is of primary concern in the development of a new genetic medicine like Rexin-G. Moreover, the establishment of a functional dose-response relationship is of fundamental significance, not only in terms of basic pharmacology, but in establishing the physiological mechanisms-of-action that are of major importance in determining the predictability of a new anti-cancer agent and ultimately in gaining full regulatory approval for Rexin-G in the United States.
Based on the scientific and medicinal merits of Rexin-G, as well as the rarity, seriousness, and lack of effective therapies for metastatic cancers, the granting of a third Orphan Drug Designation by the FDA at this time is both encouraging and confirmatory. Orphan Drug Designation provides important economic incentives and powerful market protections that encourage the development of innovative products in the cancer field. U.S. Orphan Drug Designation provides seven years of market exclusivity for Rexin-G, a reduction in fees and taxes, and additional regulatory support for ongoing R&D initiatives.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about our pipeline of biotechnologies and products that are currently available for licensing and clinical development, please visit our website, www.epeiusbiotech.com.
For more information about Rexin-G, on-going clinical trials in the USA and abroad, please contact Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.
NEWS SOURCE: Epeius Biotechnologies Corporation
Send2Press® is the originating wire service for this story. Terms of Use
THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE, WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE (SEND2PRESS® NEWSWIRE).
Latest News from Send2Press Newswire:
Additional News on Similar Topics:
| » |
Lower Back Pain is Targeted by LifeModeler, Inc. with Newly Released Software
|
| » |
FDA Grants Epeius Biotechnologies' Rexin-G A Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
|
| » |
Epeius Biotechnologies Leads with Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma RandD Summit Conference in Boston
|
| » |
California Biotechnology Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial Using Rexin-G(TM), a Targeted Injectable Gene Delivery System
|
| » |
Osmetech Licenses Self-Assembling Monolayer (SAM) Technology to Minerva Biotechnologies Corporation
|
| » |
Mark Whitacre, Ph.D. Joins Management Team at Cypress Systems, Inc.
|
| » |
Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology and the Clinical Development of its Lead Anti-Cancer Agent, Rexin-G(TM), at Upcoming Bioventure, Nanotechnology and Nanomedicine Conferences
|
| » |
Rexin-G(TM), The World's First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic Cancer
|
| » |
Epeius Biotechnologies Affirms Leadership Role in The Development of Genetic Medicine
|
| » |
Reaction Biology Corp. Awarded NIH SBIR Grant for Kinase Radioisotope Microarray Screening Development
|
| » |
Key Organics Ltd and Reaction Biology Corporation Announce New Library Screening Format
|
| » |
Epeius Biotechnologies Establishes Corporate Headquarters in San Marino, California - Facilities Include a Clinical Research Unit Dedicated to Evaluating New Genetic Medicine for Cancer
|
| » |
Reaction Biology Corp. Awarded Phase II SBIR Grant for Drug Discovery
|
| » |
Clinical Trial For Pancreatic Cancer Opens at Mayo Clinic Using Tumor-Targeted Gene Therapy Vector
|
| » |
Reaction Biology Corporation Awarded NIH Kinase Grant
|
|
» View All News Channels
» Press Release Services
» Home Page
|
|
More News from this Company
Reader Resources
Share or Save Story with Bookmarks
Use one of the link buttons, below, to save, share, or bookmark this page for friends and/or future reference.
|
Subscribe Using Popular Social Tools
Use these tools to "subscribe" to the Send2Press Newswire feed of daily news content.
 Follow on Twitter
Choose RSS Feeds by News Topic
|
|
|
Main Send2Press® News Channels
Subscribe to Weekly News Alert
from Send2Press Newswire
Get a free weekly summary of our top newswire stories at the end of each week. Privacy protected and one-click removal in each summary. This is a "double opt-in" subscription, requiring clicking acceptance link in confirmation email.
Privacy Statement
How to Unsubscribe
|
Free News Feeds for Your Blog or Website!
Add news like this to your website with one click.
Simple Javascript copy-paste, or full RSS 2.0,
or Wordpress plugin.
Best of all, it's totally FREE!
Choose from city, state, or industry topics (over 300!). Most main topics updated weekly including business, entertainment and technology news.
CLICK HERE to LEARN MORE
|
|
| |
| | U.S. and World News |
| | Advertising and Marketing |
| | Aerospace and Aviation |
| | Agriculture and Farming |
| | Apple, Mac, iPod and iPhone |
| | Auction and Online Auctions |
| | Auto and Motorsports |
| | Banking and Finance |
| | Beauty Products |
| | Boating, Marine and Maritime |
| | Business |
| | Communication Arts |
| | Company Profiles |
| | Computing |
| | Construction and Building |
| | Corporate Social Responsibility - CSR |
| | Defense and Military |
| | Education and Schools |
| | Electronics |
| | Employment, HR and Outsourcing |
| | Energy, Oil and Gas |
| | Entertainment |
| | Environment and Ecology |
| | Facilities and Building Maintenance |
| | Family, Parenting and Children |
| | Food and Beverages |
| | General Editorial |
| | Global Aid and Relief |
| | Government |
| | Green Business |
| | Health, Diet and Fitness |
| | Home and Garden |
| | HVAC Heating and Cooling |
| | Insurance |
| | Internet and Websites |
| | Jewelry and Diamond |
| | Legal and Law |
| | Manufacturing |
| | Medical |
| | Alternative Medicine |
| | Biotechnology |
| | Cosmetic Surgery |
| | Dentistry |
| | Devices and Research |
| | Disabilities and 508 Compliance |
| | Drug Rehabilitation |
| | Drugs and Pharmaceuticals |
| | Fertility and IVF |
| | Hospitals and Nursing |
| | Long Term Care |
| | Medical and Health Products |
| | Medical Business Services |
| | Ophthalmology and Vision |
| | Private Practice and Medical Groups |
| | Surgery and Neurotechnology |
| | Mining and Metals |
| | Mortuary and Cemetery |
| | NonProfit and Charities |
| | Plastics and Composites |
| | Police, Fire and Rescue |
| | Real Estate |
| | Regional Events |
| | Religion and Churches |
| | Restaurant, Hotel and Hospitality |
| | Safety and Security Solutions |
| | Sciences |
| | Sports and Activities |
| | Stamps, Coins and Collectables |
| | Taxes and Accounting |
| | Telecommunications and VoIP |
| | Theme Parks and Attractions |
| | Trade Shows, Fairs and Expos |
| | Transportation |
| | Travel and Tourism |
| | US and World History |
| | Veterinary and Pets |
| |
| | U.S. State Newswires |
| | Alabama Business |
| | Alaska Business |
| | Arizona Business |
| | California Business |
| | Colorado Business |
| | Connecticut Business |
| | Delaware Business |
| | Florida Business |
| | Georgia Business |
| | Hawaii Business |
| | Idaho Business |
| | Illinois Business |
| | Indiana Business |
| | Iowa Business |
| | Kansas Business |
| | Kentucky Business |
| | Louisiana Business |
| | Maine Business |
| | Maryland Business |
| | Massachusetts Business |
| | Michigan Business |
| | Minnesota Business |
| | Mississippi Business |
| | Missouri Business |
| | Montana Business |
| | Nebraska Business |
| | Nevada Business |
| | New Hampshire Business |
| | New Jersey Business |
| | New Mexico Business |
| | New York Business |
| | North Carolina Business |
| | Ohio Business |
| | Oklahoma Business |
| | Oregon Business |
| | Pennsylvania Business |
| | Puerto Rico Business |
| | South Carolina Business |
| | South Dakota Business |
| | Tennessee Business |
| | Texas Business |
| | Utah Business |
| | Vermont Business |
| | Virginia Business |
| | Washington D.C. Business |
| | Washington State Business |
| | West Virginia Business |
| | Wisconsin Business |
| |
| | Video News Releases |
| |
| | World Newswires |
| | Australia Business |
| | Brazil Business |
| | Canada Business |
| | China Business |
| | Germany Business |
| | Italy Business |
| | Spain Business |
| | United Kingdom |
|
Terms of Use and License
This "article" version of the issued press release is Copr. © 1983-2009 Neotrope/Send2Press. You may freely link to this article version of the press release or may use the release text as the basis for an original article or news posting. If the content is copied verbatim via a scraping or copy/paste method, the news item must be properly "attributed" to Send2Press® Newswire as the originating wire service for this story.
|
DISCLAIMER: the above press release content is believed accurate but not guaranteed, and is based on business news supplied by the source. The noted source is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements. Neotrope/Send2Press (this website) makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news and profiles are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope® or Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.
REFERENCES: FDA Grants Epeius Biotechnologies' Rexin-G A Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas, Epeius Biotechnologies Corporation, biopharmaceutical company, Dr. Erlinda M. Gordon, Soft Tissue Sarcomas, genetic medicine like Rexin-G, FDA, Orphan Drug Designation by the U.S. Food and Drug Administration, Jul 8, 2008.
|
|
|
Search Send2Press.com:
Google
Reddit
Diigo
Delicious
Yahoo!
Digg
Blinklist
Blogmarks
Mixx
Facebook
Newsvine
